Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing multivalent recombinant Marek's Disease virus (rMDVnp) vectors struggle to stably express antigens from multiple poultry viruses, leading to unpredictable vaccine efficacy and stability, particularly when combining heterologous antigens from different pathogens.

Innovation Solution

A novel recombinant non-pathogenic Marek's Disease virus (rMDVnp) vector, such as rHVT or rMDV2, is designed to express foreign genes from Infectious Laryngotracheitis Virus (ILTV) and Infectious Bursal Disease Virus (IBDV) by inserting nucleotide sequences into nonessential sites of the rMDVnp genome, using specific promoters and transcription terminators to ensure stable expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If multiple recombinant monovalent rMDVnp constructs are used to provide multivalent protection, then protection against multiple viral pathogens is achieved, but one construct overgrows the others preventing significant immune response

Engineering Contradiction:

Improveprotection against multiple viral pathogensVSAvoidimmune response stability

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent combines multiple viral antigen genes (ILTV gD, IBDV VP2, NDV F) into a single recombinant rMDVnp construct, creating a unified multivalent vaccine that eliminates competitive overgrowth between separate constructs while maintaining stable expression of all antigens

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The rMDVnp vector is designed as a universal platform capable of expressing multiple different viral antigens simultaneously through a single construct, providing multivalent protection against ILTV, IBDV, and NDV through one vaccine formulation

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Adaptability or versatility

If multiple separate injections are given to achieve multivalent protection, then protection against multiple pathogens is achieved, but discomfort and stress on the chick increases

Engineering Contradiction:

Improveprotection against multiple pathogensVSAvoidvaccination process simplicity

Core Design Contradiction:

Adaptability or versatilityVSEase of operation

Solution Approach 1:

The patent merges multiple vaccine antigens into a single recombinant rMDVnp construct that can be administered in one injection, eliminating the need for multiple separate vaccinations and reducing stress on vaccinated chicks

Inventive Principle:

Principle #5Merging (Combining)

3Adaptability or versatility

If multiple separate injections are used for multivalent vaccination, then protection against multiple pathogens is achieved, but labor and material costs increase

Engineering Contradiction:

Improveprotection against multiple pathogensVSAvoidvaccination efficiency

Core Design Contradiction:

Adaptability or versatilityVSProductivity

Solution Approach 1:

The patent combines multiple viral antigens into a single multivalent rMDVnp construct, reducing the number of vaccinations required and thereby decreasing labor and material costs associated with multiple separate injections

Inventive Principle:

Principle #5Merging (Combining)

4Adaptability or versatility

If heterologous antigens from multiple pathogens are expressed in rMDVnp, then multivalent protection is achieved, but expression stability becomes unpredictable

Engineering Contradiction:

Improveexpression of multiple viral antigensVSAvoidantigen expression stability

Core Design Contradiction:

Adaptability or versatilityVSStability of the object's composition

Solution Approach 1:

The patent places different viral antigen genes into specific nonessential genomic sites of rMDVnp (US2, UL7/8, US10, UL54.5 regions) with optimized local regulatory elements, ensuring stable and predictable expression of each antigen while maintaining overall construct stability

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12514922B2Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens

Publication Date: 2026.01.06 INTERVET INC

AI summary

The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.